AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 SEP 2 - (NewsRx.com & NewsRx.net) -- A discussion of hormone therapy for menopausal women who've had endometrial cancer was presented recently in the journal Endocrine-Related Cancer.
Authors A.O. Mueck and colleagues, Women's University Hospital, Tubingen, Germany, wrote: "Endometrial carcinoma is listed under the absolute contraindications to hormone therapy (HT).
"According to current opinion, HT after stage I or II is still considered an option, and continuous combined estrogen/progestogen replacement therapy (CCEPT) would be recommended. However, up to now, only observational studies have been put forward.
"Although none of these studies have established an increased rate of recurrence or mortality, alternatives such as phytopreparations and tibolone, or particular psychotherapeutic drugs, such as venlafaxine, should be considered for the relief of climacteric complaints," Mueck and colleagues stated.
They noted that progestogen-only therapy (PT) in particular has been considered. "However, the currently discussed possible progestogen effects regarding an increased risk of breast cancer have to be taken into account," they said.
"Indeed," the authors continued, "the wider discussion about the gestagen effects regarding the risk of breast cancer is to be considered.
"Generally, after hysterectomy, at least for patients with ...
Source: HighBeam Research, Some hormone therapy options can be considered after endometrial...